Browsing category:

NDA


Dapagliflozin, CAS number 461432-26-8, is currently being reviewed by the FDA for treatment of type 2 diabetes in adults. Developed by Bristol-Myers Squibb and AstraZeneca, the method of action of dapagliflozin is to inhibit the subtype 2 of the sodium-glucose transport proteins, or SGLT2. This particular subtype is responsible for at least 90% of the[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service